Articles in this Issue

  • Application of Raman Spectroscopy in Establishing Solid Form Integrity for a Highly Polymorphic...

    Paul E. Luner, Ph.D., Shawn Mehrens
    Polymorph and crystal form control is an essential part of development of active pharmaceutical ingredients (API) [1]. Processing steps such as milling for API particle size reduction or those involved in the solid dosage form processing have potential to alter the input crystal form and this is often referred to as Process Induced Transformation (PIT). The impact and mechanisms of processing stress on phase transformation have been well reviewed and examples are provided [2-5]. Although basic physical characterization techniques can be successfully applied at the API level for form assessment, detection of low levels of different crystal forms within a dosage form on a routine or release basis can require significant effort and can be challenging because of detection limits and specificity
  • The Antimicrobial Efficacy Test, GMP and Investigations

    Scott Sutton, Ph.D.
    The USP Antimicrobial Effectiveness Test (AET) is a product quality test which is designed to be, so far as is possible, a reproducible biological measurement of the activity of the preservative system in a product. This test is required for multi-dose presentations of pharmaceuticals as well as anhydrous ointments that contain a preservative system [1].
  • Ancient and Modern Endotoxin Biosensors: Evolutionary Perspectives Inform LAL Technologies

    Kevin L. Williams
    Since the inception of Limulus amebocyte lysate (LAL) testing [1], the past four decades of testing have proven fruitful in terms of making in-vitro predictions of in vivo responses regarding the significant pyrogen of drug manufacturing, bacterial endotoxin. The Limulus test has served as the basis of preclusion of bacterial endotoxin in drug products for these many years. However, current discoveries elucidating the mechanisms by which endotoxin interacts with host biosensors in both invertebrates and vertebrates is turning many a preconceived notion on its head.
  • Implications of the Human Microbiome on Pharmaceutical Microbiology

    Cara N. Wilder, Ph.D.,, Tim Sandle, PhD, Scott Sutton, Ph.D.
    The human body is a composite of human cells that survive interdependently alongside complex, interconnected microbial populations, their genetic elements (genomes), and environmental interactions.
  • At Scale Analysis and Optimization of a Cell Culture Harvest Process– Mitigating Risk and Optimizing...

    Michael Pohlscheidt, Goetz Lieser, Bjoern-Erec Bertermann, Horst Eberhardt, Stefan Herter, Hermann Tebbe
    Recombinant DNA technology has enabled the industrial production of monoclonal antibodies and recombinant proteins for targeted treatments of several diseases such as cancer and viral infections.
  • Analytical Quality by Design (AQbD) in Pharmaceutical Development

    George L. Reid, Ph.D., James Morgado, Kimber Barnett, Ph.D, Brent Harrington, Jian Wang, Ph.D, Jeff Harwood, David Fortin
    The concepts described in ICH Q8-Q11, commonly referred to as Quality by Design (QbD), have also been applied to the development of analytical methods.
  • Nanopreparations for Delivery of Non-Deliverable Pharmaceuticals

    Vladimir Torchilin, Ph.D.
    Traditional pharmaceuticals rarely demonstrate specific affinity towards the site of their action and as a rule, they distribute throughout the body upon administration. To reach the action site, a pharmaceutical agent has to overcome the inactivating action of the aggressive biological medium and cross a variety of biological barriers, which frequently results in at least partial drug inactivation/degradation and unfavorable pharmacokinetics and biodistribution. In addition, many pharmaceutical agents could provoke multiple undesirable side effects in normal organs, tissues and cells. To solve these complicating issues, various systems for drug delivery are suggested, and some of those even have already found their way to clinic.
  • An Interview With Michael E. Dawson, Ph.D., RAC (Director of Regulatory Affairs Associates...

    Associates of Cape Cod, Inc.’s (ACC) fourth generation tube reader, the Pyros® Kinetix Flex, offers the most sensitive bacterial endotoxin test (BET) available for both turbidimetric and chromogenic kinetic methods. In addition to flexibility of test method, ACC offers a choice of 32, 64 and 96 well readers. All of these readers provide the flexibility to add tubes at any time. Unlike a microplate reader, additional samples can be added after a test has been started. Also, we shall soon have an exciting new offering in the area of endotoxin testing.
  • An Interview With Brian Thompson (Vice President Demand Supply Chain and Purchasing DSM Pharmaceuticals,...

    From a CMO’s perspective, serialization should help prevent fraud and help DSM as well as its customers’ research any issues reported downstream in the supply chain. Through serialization and other technologies like video surveillance, DSM will have the ability to investigate primary and secondary packaging units to the exact time they were packaged during a standard packaging run.
  • The Advantages of Using Automation in Pharmaceutical Environmental Monitoring

    Anna Mills
    Environmental Monitoring is an essential component to any microbiological testing regime. Unfortunately, the task is often time consuming due to the large volumes of tests and the length of time required for sample capture, processing and incubation of samples. Reading such high volumes of plates adds an extra time constraint for the Microbiologist and a risk of human error element. The Growth directTM System has been designed to cut both the work load and reduce risk to create a leaner, more efficient laboratory.
  • Use of Stressed Populations for Application Validation to Better Represent Real World Testing

    Andrew Sage, Ph.D.
    The goal of microbial testing is to detect contamination that is present in, or introduced into sample matrices such as controlled manufacturing environments (air, surfaces, personnel), waters, and raw, in-process, and final product materials among many others. Like any testing application, the methods must be validated to confirm their effectiveness in detecting microbial contaminants from the particular sample matrix in question.
  • Pharmaceutical Product Impurities: Considering Beta Glucans

    Tim Sandle, PhD
    There are many pharmacological impurities which can appear, through unintended routes, in formulated final products. Although undesirable in terms of not meeting the strict requirements of a prepared product, the impact upon the drug formulation and potential impact upon the patient will vary according to the type and concentration of the impurity.
  • <<
  • >>